Treatment of Oral Lichen Planus

First-Line Treatment Options

The National Comprehensive Cancer Network recommends high-potency topical corticosteroids as the first-line treatment for oral lichen planus, with clobetasol 0.05% or fluocinonide 0.05% gel being the most effective options for mucosal disease 1, 2
Topical corticosteroids, such as clobetasol propionate 0.05% gel and fluocinonide 0.05% gel, are recommended for all grades of oral lichen planus 1, 2
The National Comprehensive Cancer Network suggests topical calcineurin inhibitors, such as tacrolimus 0.1% ointment, as an alternative first-line option when corticosteroids are contraindicated or ineffective 1, 2

For mild to moderate disease, the National Comprehensive Cancer Network recommends starting with high-potency topical corticosteroids in gel form for 2-3 months 1, 2
For moderate to severe disease, the National Comprehensive Cancer Network suggests continuing topical corticosteroids and considering adding oral antihistamines, short course of oral prednisone, or narrow-band UVB phototherapy 1, 2
For refractory cases, the National Comprehensive Cancer Network recommends considering doxycycline with nicotinamide or referral to dermatology for systemic immunomodulators 1, 2

The National Comprehensive Cancer Network recommends treating until symptoms improve to Grade 1, then tapering over 3 weeks 1
Gel formulations are preferred for oral mucosal disease, and regular follow-up is necessary to assess response and monitor for adverse effects 1, 2
Failure to taper corticosteroids gradually can lead to rebound flares, and using cream/ointment formulations instead of gels for oral mucosal disease is not recommended 1, 2

The NCCN recommends adding oral antihistamines for patients with moderate‑to‑severe lichen planus to control symptoms such as pruritus. (Evidence level not specified) 3

For individuals with widespread cutaneous involvement, the NCCN suggests using narrow‑band UVB phototherapy as an adjunct to high‑potency topical corticosteroids. (Evidence level not specified) 3

In refractory cases, the NCCN advises referral to dermatology for consideration of systemic immunomodulators—including methotrexate, hydroxychloroquine, azathioprine, cyclosporine, or mycophenolate mofetil—when steroid‑sparing treatment is required. (Evidence level not specified) 3